Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE

Ascelia Pharma AB (publ) (ticker: ACE) today published its interim financial report for Q1-2020 (January – March 2020), which is now available on the company’s website:


  • First patient enrolled in Mangoral’s Phase 3 study SPARKLE
  • Additional clinical sites opened for patient enrolment
  • Ascelia Pharma wins the award as the best Life Science company in Malmö, Sweden


  • Patent for Oncoral approved in Japan
  • First participant enrolled in the clinical hepatic impairment study with Mangoral


  • Operating result of SEK -20.7M (SEK -11.7M)
  • Earnings per share of SEK -0.71 (SEK -0.68)
  • Cash flow from operations of SEK -18.4M (SEK -3.0M)
  • Cash and marketable securities of SEK 169.3M (SEK 219.1M)

“The first quarter of 2020 was a transformative period for Ascelia Pharma as we enrolled the first patient in SPARKLE, our registration-enabling clinical study of Mangoral and are thereby now a fully-fledged Phase 3 company. Looking ahead, our focus for 2020 is on the SPARKLE study and preparations for a commercial launch of Mangoral“, said Magnus Corfitzen, CEO at Ascelia Pharma.

A presentation for analysts, media and investors will be held on 13 May at 10:00am CET. The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos, CMO Carl Bjartmar and CCO Julie Waras Brogren. The presentation will be held in English. The presentation can be followed live via the link:

It will also be possible to take part of the audiocast afterwards at the same address or at Ascelia Pharma’s website:

To participate in the telephone conference, please use the dial-in details shown below:
SE: +46 856 642 693
UK: +44 333 300 9030 
US: +1 833 823 0590

For more information, please contact
Magnus Corfitzen, CEO
Tel: +46 735 179 118

Mikael Widell, IR & Communications Manager
Tel: +46 703 11 99 60

The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on 13 May 2020.

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral and Oncoral – currently under development.

Mangoral (manganese chloride tetrahydrate) is a novel oral contrast agent for MRI-scans, currently being evaluated in the pivotal Phase 3 clinical study SPARKLE. Mangoral is developed to improve the visualisation of focal liver lesions (liver metastases or primary tumours) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase 2 for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit